220. Back to Basics - Central Nervous System Tumours
from Oncology for the Inquisitive Mind
This episode is about IDH-mutant glioma, a cancer that often hits people in their thirties and forties who may live for decades, which makes the long-term cost of treatment matter as much as the benefit. We’re looking at two trials, almost thirty years apart. RTOG 9402 opened in 1994 and asked whether adding PCV chemotherapy to radiotherapy did better than radiotherapy alone in anaplastic oligodendroglioma. INDIGO asked whether a daily tablet, the IDH inhibitor vorasidenib, could let patients with grade 2 disease put off radiotherapy and chemotherapy altogether. One asks whether more is better. The other asks whether we can safely wait. What did they find, and what do they mean for the patient in front of you on Monday? Let’s get into it. Studies Discussed in Today's Episode RTOG 9402 INDIGO For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at [email protected] Art courtesy of Taryn Silver Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/ Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.
Embed this episode
No transcript yet.